CU20040029A7 - Cristales anhidros que incluyen una sal del ácido málico de una 2-indolinona sustituida con 3-pirrol, métodos de preparación y composiciones que las contienen - Google Patents

Cristales anhidros que incluyen una sal del ácido málico de una 2-indolinona sustituida con 3-pirrol, métodos de preparación y composiciones que las contienen

Info

Publication number
CU20040029A7
CU20040029A7 CU20040029A CU20040029A CU20040029A7 CU 20040029 A7 CU20040029 A7 CU 20040029A7 CU 20040029 A CU20040029 A CU 20040029A CU 20040029 A CU20040029 A CU 20040029A CU 20040029 A7 CU20040029 A7 CU 20040029A7
Authority
CU
Cuba
Prior art keywords
degrees
acid salt
anhyding
pirrol
indolinone
Prior art date
Application number
CU20040029A
Other languages
English (en)
Other versions
CU23713B7 (es
Inventor
Mark T Maloney
Stephen P Prescot
Thomas J Fleck
Michael Hawley
Original Assignee
Pharmacia & Amp
Upjohn Company Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23211067&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CU20040029(A7) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacia & Amp, Upjohn Company Llc filed Critical Pharmacia & Amp
Publication of CU20040029A7 publication Critical patent/CU20040029A7/es
Publication of CU23713B7 publication Critical patent/CU23713B7/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Cristales anhidros de una sal de ácido málico de un compuesto que tiene la estructura: ESPACIO PARA FÓRMULA donde el cristal es preferentemente ácido málico es ácido L-málico o una sal del ácido málico de N-[2-(dietilamino)etil]-5-[(5-fluoro-1,2-dihidro-2-oxo-3H-indol-3-iliden)metil]-2,4-dimetil-1H-pirrol-3-carboxamida, y tiene picos de difracción característicos a aproximadamente 13,2 y 24,2 grados dos teta (forma cristalina I) en un patrón de difracción de polvo por rayos X, preferentemente a aproximadamente 13,2, 19,4, 24,2 y 25,5 grados dos teta, o picos de difracción característicos a aproximadamente 3,0 y 27,2 grados dos teta en un patrón de difracción del polvo por rayos X, preferentemenete a aproximadamente 13,2, 19,4, 24,2 y 25,5 grados dos teta (forma cristalina II) en un patrón de difracción del polvo por rayos X, preferentemente a aproximadamente 3,0, 12,1, 14,5 y 27,7 grados teta; métodos para preparar dichos cristales anhidros; y composición que los comprende.
CU20040029A 2001-08-15 2004-02-12 Cristales anhidros que incluyen una sal del ácido málico de una 2-indolinona sustituida con 3-pirrol, métodos de preparación y composiciones que las contienen CU23713B7 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US31235301P 2001-08-15 2001-08-15

Publications (2)

Publication Number Publication Date
CU20040029A7 true CU20040029A7 (es) 2008-03-14
CU23713B7 CU23713B7 (es) 2011-10-05

Family

ID=23211067

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20040029A CU23713B7 (es) 2001-08-15 2004-02-12 Cristales anhidros que incluyen una sal del ácido málico de una 2-indolinona sustituida con 3-pirrol, métodos de preparación y composiciones que las contienen

Country Status (43)

Country Link
US (2) US20030069298A1 (es)
EP (3) EP3168218B1 (es)
JP (1) JP4159988B2 (es)
KR (1) KR100639281B1 (es)
CN (2) CN100439360C (es)
AP (1) AP1660A (es)
AR (1) AR036261A1 (es)
AU (1) AU2002324684B2 (es)
BG (1) BG108553A (es)
BR (1) BR0211612A (es)
CA (1) CA2455050C (es)
CO (1) CO5550431A2 (es)
CU (1) CU23713B7 (es)
CY (1) CY1121552T1 (es)
CZ (1) CZ2004196A3 (es)
DK (2) DK3168218T3 (es)
EA (1) EA006445B9 (es)
EC (1) ECSP044975A (es)
ES (3) ES2453164T3 (es)
GE (1) GEP20063777B (es)
HK (2) HK1066542A1 (es)
HR (1) HRP20040112B1 (es)
HU (1) HU229206B1 (es)
IL (1) IL160097A0 (es)
IS (1) IS7147A (es)
MA (1) MA27058A1 (es)
ME (1) ME00414B (es)
MX (1) MXPA04001452A (es)
MY (1) MY139383A (es)
NO (1) NO326508B1 (es)
NZ (1) NZ531232A (es)
OA (1) OA12650A (es)
PL (1) PL216524B1 (es)
PT (2) PT3168218T (es)
RS (1) RS53251B (es)
SI (2) SI3168218T1 (es)
SK (1) SK902004A3 (es)
TN (1) TNSN04028A1 (es)
TR (1) TR201900509T4 (es)
TW (1) TWI269796B (es)
UA (1) UA76483C2 (es)
WO (1) WO2003016305A1 (es)
ZA (1) ZA200400706B (es)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3168218T (pt) 2001-08-15 2019-01-11 Pharmacia & Upjohn Co Llc Um cristal compreendendo um sal de ácido l-málico de n-[2- (dietilamino)etil]-5-[(5-fluoro-1,2-dihidro-2-oxo-3h-indol- 3-ilideno)metil]-2,4-dimetil-1h-pirrol-3-carboxamida para utilização como um medicamento
HN2003000272A (es) * 2002-09-10 2008-07-29 Pharmacia Italia Spa Formulaciones que comprenden un compuesto de indolinona
KR20060058728A (ko) * 2003-10-02 2006-05-30 파마시아 앤드 업존 캄파니 엘엘씨 피롤-치환된 인돌리논 화합물의 염 및 다형체
US20060009510A1 (en) * 2004-07-09 2006-01-12 Pharmacia & Upjohn Company Llc Method of synthesizing indolinone compounds
EP1773811B1 (en) * 2004-07-22 2010-09-08 Eli Lilly And Company A crystalline variable hydrate of (s)-6-(4-(2-((3-(9h-carbazol-4-yloxy)-2-hydroxypropyl)amino)-2-methylpropyl)phenoxy)-3-pyridinecarbox amide hemisuccinate salt
KR20070119745A (ko) * 2005-05-12 2007-12-20 화이자 인코포레이티드 수니티닙 말레이트를 사용하는 항암 병행 요법
SI1928858T1 (sl) * 2005-09-19 2009-10-31 Pfizer Prod Inc Trde solne oblike s pirolom substituiranega 2-indolinona
US20090004213A1 (en) * 2007-03-26 2009-01-01 Immatics Biotechnologies Gmbh Combination therapy using active immunotherapy
EP2253629A1 (en) * 2007-11-21 2010-11-24 Teva Pharmaceutical Industries Ltd. Polymorphs of racemic sunitinib malate, compositions containing them and preparation thereof
US20100256392A1 (en) * 2007-11-21 2010-10-07 Teva Pharmaceutical Industries Ltd. Polymorphs of sunitinib base and processes for preparation thereof
CN101939314B (zh) * 2007-12-12 2014-04-02 麦迪凯姆股份公司 3-吡咯取代的2-吲哚酮的多晶型物
EP2090306A1 (en) 2008-02-13 2009-08-19 Ratiopharm GmbH Pharmaceutical compositions comprising N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
EP2113248A1 (en) 2008-04-29 2009-11-04 Ratiopharm GmbH Pharmaceutical composition comprising N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2-,4-dimethyl-1H-pyrrole-3-carboxamide
JP2011512396A (ja) * 2008-02-21 2011-04-21 ジェネリクス・（ユーケー）・リミテッド 新規な多形およびその調製方法
EP2098521A1 (en) * 2008-03-06 2009-09-09 Ratiopharm GmbH Crystal forms of N-[2-(diethylamino) ethyl]-5-[fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrolle-3-carboxamide and methods for their prepparation
JP2011516488A (ja) * 2008-03-31 2011-05-26 テバ ファーマシューティカル インダストリーズ リミティド スニチニブ及びその塩の調製方法
KR20100135910A (ko) 2008-04-16 2010-12-27 낫코 파마 리미티드 수니티닙 염기의 신규한 다형 형태
CN102066362B (zh) * 2008-05-23 2014-07-30 上海医药工业研究院 二氢吲哚酮衍生物
EP2313371B1 (en) * 2008-06-13 2012-08-15 Medichem, S.A. Process for preparing a 3-pyrrole substituted 2-indolinone malate salt
EP2138167A1 (en) 2008-06-24 2009-12-30 ratiopharm GmbH Pharmaceutical composition comprising N-[2-(Diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene) methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
WO2009156837A2 (en) * 2008-06-26 2009-12-30 Medichem, S.A. Amorphous form of a 3-pyrrole substituted 2-indolinone malate salt
WO2010004339A1 (en) 2008-07-10 2010-01-14 Generics [Uk] Limited Processes for the preparation of crystalline forms of sunitinib malate
EP2342195B1 (en) 2008-07-24 2014-09-10 Medichem, S.A. Crystalline forms of a 3-pyrrole substituted 2-indolinone malate salt
KR20110036588A (ko) 2008-07-24 2011-04-07 테바 파마슈티컬 인더스트리즈 리미티드 수니티닙 아세테이트 및 이의 다형을 통한 수니티닙 말레이트의 제조 방법
WO2010023473A2 (en) * 2008-08-25 2010-03-04 Generics [Uk] Limited Novel crystalline form and processes for its preparation
JP2012500838A (ja) * 2008-08-25 2012-01-12 ジェネリクス・（ユーケー）・リミテッド スニチニブの新規な多形およびその調製方法
EP2350056A1 (en) * 2008-10-10 2011-08-03 Medichem, S.A. Process for preparing a 3-pyrrole subsituted 2-indolinone malate salt
EP2181991A1 (en) 2008-10-28 2010-05-05 LEK Pharmaceuticals D.D. Novel salts of sunitinib
EP2186809A1 (en) * 2008-11-13 2010-05-19 LEK Pharmaceuticals D.D. New crystal form of sunitinib malate
EP2373643A4 (en) * 2009-01-02 2013-08-07 Hetero Research Foundation NEW SUNITINIB MALATE POLYMORPHS
KR101733773B1 (ko) 2009-01-16 2017-05-10 엑셀리시스, 인코포레이티드 Ｎ-（４-｛〔６，７-비스（메틸옥시）퀴놀린-4-일〕옥시｝페닐）-ｎ＇-（４-플루오로페닐）사이클로프로판-1,1-디카르복사미드의 말산염 및 그 결정형
EP2255792A1 (en) 2009-05-20 2010-12-01 Ratiopharm GmbH Pharmaceutical compositions for N-[2-(Diethylamino)ethyl]5-[(fluoro-1,2-dihydro-2-oxo-3H-indole-3-ylidene) methyl]-2,4-dimenthyl-1H-pyrrole-3-carboxamide
WO2011004200A1 (en) 2009-07-10 2011-01-13 Generics [Uk] Limited Novel pyrrole derivatives
EP2477978A1 (en) 2009-09-16 2012-07-25 Ranbaxy Laboratories Limited Salts of sunitinib
EP2499133A2 (en) * 2009-11-12 2012-09-19 Ranbaxy Laboratories Limited Process for the preparation of crystalline form i of l-malic acid salt of sunitinib
WO2011061613A1 (en) 2009-11-19 2011-05-26 Ranbaxy Laboratories Limited Process for the preparation of crystalline form ii of l-malic acid salt of sunitinib
EP2528913A1 (en) 2010-01-29 2012-12-05 Ranbaxy Laboratories Limited Crystalline forms of l-malic acid salt of sunitinib
WO2011100325A2 (en) 2010-02-09 2011-08-18 Sicor Inc. Polymorphs of sunitinib salts
WO2011104555A2 (en) 2010-02-25 2011-09-01 Generics [Uk] Limited Novel process
US20130123511A1 (en) 2010-03-04 2013-05-16 Ranbaxy Laboratories Limited Process for the direct preparation of malic acid salt of sunitinib
WO2011114246A1 (en) 2010-03-18 2011-09-22 Ranbaxy Laboratories Limited Process for the preparation of malic acid salt of sunitinib
WO2011128699A2 (en) 2010-04-16 2011-10-20 Generics [Uk] Limited Novel process
WO2012042421A1 (en) 2010-09-29 2012-04-05 Pfizer Inc. Method of treating abnormal cell growth
DK2699598T3 (en) 2011-04-19 2019-04-23 Pfizer COMBINATIONS OF ANTI-4-1BB ANTIBODIES AND ADCC-INducing ANTIBODIES FOR TREATMENT OF CANCER
ES2709110T3 (es) 2012-03-23 2019-04-15 Laurus Labs Ltd Un proceso mejorado para la preparación de sunitinib y sus sales de adición de ácido
PL399027A1 (pl) 2012-04-27 2013-10-28 Instytut Farmaceutyczny Sposób otrzymywania N-[2-(dietylamino)etylo]-5-formylo-2,4-dimetylo-1H-pirolo-3-karboksyamidu o wysokiej czystosci i jego zastosowanie do wytwarzania sunitynibu
CN104284674A (zh) 2012-05-04 2015-01-14 辉瑞公司 ***相关抗原及基于疫苗的免疫治疗疗法
CA2838587A1 (en) 2013-10-18 2015-04-18 Hari Babu Matta Pure crystalline form ii of l-malic acid salt of sunitinib and processes for its preparation
CA2838585A1 (en) * 2013-10-18 2015-04-18 Hari Babu Matta An ascorbic acid salt of sunitinib
PE20171142A1 (es) 2013-11-01 2017-08-10 Pfizer Vectores para expresion de antigenos asociados a prostata
CN104693187A (zh) * 2013-12-10 2015-06-10 安杰世纪生物科技（北京）有限公司 一种舒尼替尼L-苹果酸盐晶型λ及其制备方法
CN104744442B (zh) * 2013-12-25 2019-05-28 江苏豪森药业集团有限公司 苹果酸舒尼替尼的制备方法
RU2567535C1 (ru) * 2014-10-01 2015-11-10 Олег Ростиславович Михайлов КРИСТАЛЛИЧЕСКАЯ ε-МОДИФИКАЦИЯ N-[2-(ДИЭТИЛАМИНО)ЭТИЛ]-5-[(Z)-(5-ФТОР-1,2-ДИГИДРО-2-ОКСО-3Н-ИНДОЛ-3-ИЛИДЕН)МЕТИЛ]-2,4-ДИМЕТИЛ-1Н-ПИРРОЛ-3-КАРБОКСАМИД МАЛАТА, СПОСОБ ЕЕ ПОЛУЧЕНИЯ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ЕЕ ОСНОВЕ
CN105712979A (zh) * 2014-12-05 2016-06-29 广州白云山医药集团股份有限公司白云山制药总厂 一种苹果酸舒尼替尼晶型ⅰ的制备方法
EP3539536A1 (en) 2018-03-15 2019-09-18 MH10 Spolka z ograniczona odpowiedzialnoscia A pharmaceutical composition of sunitinib or its salt thereof in its polymorphic form i
WO2020216450A1 (en) 2019-04-25 2020-10-29 Synthon B.V. Pharmaceutical composition comprising amorphous sunitinib
CN113766932A (zh) * 2019-04-18 2021-12-07 米特健康有限公司 用于治疗呼吸性心律失常的方法和组合物
KR20240025990A (ko) 2022-08-19 2024-02-27 주식회사 스카이테라퓨틱스 무정형 수니티닙, 그 제조방법 및 이를 포함한 의약 조성물

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU225055B1 (en) 1990-10-15 2006-05-29 Pfizer Indole derivatives, their intermediates, process for production them and pharmaceutical compositions containing the compounds
IL100091A (en) 1990-12-12 1998-08-16 Zeneca Ltd Pharmaceutical preparations containing the physical form of [4] 5) Cyclopentyloxycarbyl (amino 1 methyl indole 3 methyl methyl [3 methoxybenzoyl [2 methylbenzole)
SK279211B6 (sk) 1992-06-05 1998-08-05 Merck Sharp & Dohme Limited Sulfátová soľ substituovaného triazolu, spôsob jej
JP3852946B2 (ja) 1993-03-12 2006-12-06 ファルマシア・アンド・アップジョン・カンパニー 結晶性セフチオフル遊離酸
US6288057B1 (en) 1994-08-31 2001-09-11 Eli Lilly And Company Physical form of dihydro-2,3-benzodiazepine derivative
DE19503966C2 (de) 1995-02-07 1998-07-02 Mack Chem Pharm Kristallmodifikation von 2,4-Diamino-6-hydroxymethylpteridin-Hydrobromid, Verfahren zu dessen Herstellung und dessen Verwendung
US5597663A (en) * 1995-05-30 1997-01-28 Motorola, Inc. Low temperature molten lithium salt electrolytes for electrochemical cells
US5880141A (en) * 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
US5673451A (en) * 1995-07-06 1997-10-07 Moore; James R. Instructional toothbrush
US20020045746A1 (en) 1995-12-11 2002-04-18 Barton Kathleen P. Eplerenone crystalline form
US20020038021A1 (en) 1995-12-11 2002-03-28 Barton Kathleen P. Eplerenone crystalline form exhibiting enhanced dissolution rate
US6066647A (en) 1996-07-29 2000-05-23 Pfizer Inc. Zwitterionic forms of trovafloxacin
RO120771B1 (ro) * 1996-08-14 2006-07-28 G.D. Searle & Co. Formă cristalină b a 4-(5-metil-3-fenilizoxazol-4-il) benzensulfonamidei
WO1998029344A1 (fr) 1996-12-25 1998-07-09 Nippon Kayaku Kabushiki Kaisha Poudre de cisplatine fine et son procede de production
US5777185A (en) * 1997-09-09 1998-07-07 Laroche Industries Inc. Production of organic fluorine compounds
US6133305A (en) * 1997-09-26 2000-10-17 Sugen, Inc. 3-(substituted)-2-indolinones compounds and use thereof as inhibitors of protein kinase activity
US6012678A (en) * 1998-01-26 2000-01-11 The Boeing Company Galley vacuum waste disposal system
DK1020454T4 (da) * 1998-06-19 2013-11-25 Teijin Ltd Polymorfe former af 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazol-carboxylsyre og fremgangsmåde til fremstilling deraf
TR200101860T2 (tr) * 1998-12-17 2001-12-21 F.Hoffmann-La Roche Ag Sikline bağlı kinaz inhibitörleri olarak 4-alkenil (ve alkinil) oksidoller
US6239141B1 (en) 1999-06-04 2001-05-29 Pfizer Inc. Trovafloxacin oral suspensions
PT1233943E (pt) 1999-11-24 2011-09-01 Sugen Inc Formulações para agentes farmacêuticos ionizáveis como ácidos livres ou bases livres
NZ520640A (en) * 2000-02-15 2005-04-29 Upjohn Co Pyrrole substituted 2-indolinone protein kinase inhibitors
US6316672B1 (en) 2001-01-31 2001-11-13 Grayson Walker Stowell Form a of fluoxetine hydrochloride
PT3168218T (pt) 2001-08-15 2019-01-11 Pharmacia & Upjohn Co Llc Um cristal compreendendo um sal de ácido l-málico de n-[2- (dietilamino)etil]-5-[(5-fluoro-1,2-dihidro-2-oxo-3h-indol- 3-ilideno)metil]-2,4-dimetil-1h-pirrol-3-carboxamida para utilização como um medicamento
JP2011512396A (ja) 2008-02-21 2011-04-21 ジェネリクス・（ユーケー）・リミテッド 新規な多形およびその調製方法
WO2009156837A2 (en) 2008-06-26 2009-12-30 Medichem, S.A. Amorphous form of a 3-pyrrole substituted 2-indolinone malate salt

Also Published As

Publication number Publication date
RS53251B (sr) 2014-08-29
PT3168218T (pt) 2019-01-11
EP2332934A1 (en) 2011-06-15
TR201900509T4 (tr) 2019-02-21
GEP20063777B (en) 2006-03-27
CA2455050A1 (en) 2003-02-27
CN1543462A (zh) 2004-11-03
IS7147A (is) 2004-02-10
MA27058A1 (fr) 2004-12-20
AR036261A1 (es) 2004-08-25
SI3168218T1 (sl) 2019-05-31
CN100439360C (zh) 2008-12-03
EA006445B9 (ru) 2017-02-28
ZA200400706B (en) 2005-05-25
EA200400183A1 (ru) 2004-08-26
HK1066542A1 (en) 2005-03-24
HK1088008A1 (en) 2006-10-27
EP1419151A1 (en) 2004-05-19
CA2455050C (en) 2007-02-20
CY1121552T1 (el) 2020-05-29
EA006445B1 (ru) 2005-12-29
EP2332934B1 (en) 2017-03-01
CN100364991C (zh) 2008-01-30
HU229206B1 (en) 2013-09-30
CU23713B7 (es) 2011-10-05
MY139383A (en) 2009-09-30
NO326508B1 (no) 2008-12-15
NO20041054L (no) 2004-03-12
ECSP044975A (es) 2004-03-23
SI1419151T1 (sl) 2014-04-30
HRP20040112A2 (en) 2004-06-30
EP3168218A1 (en) 2017-05-17
ME00414B (me) 2011-10-10
DK1419151T3 (da) 2014-03-31
JP2005503386A (ja) 2005-02-03
SK902004A3 (sk) 2005-03-04
BR0211612A (pt) 2004-08-24
US20070191458A1 (en) 2007-08-16
AU2002324684B2 (en) 2006-10-05
MXPA04001452A (es) 2004-05-20
ES2453164T3 (es) 2014-04-04
OA12650A (en) 2006-06-19
HUP0700036A2 (en) 2008-10-28
HRP20040112B1 (en) 2012-03-31
JP4159988B2 (ja) 2008-10-01
RS10304A (en) 2007-02-05
PT1419151E (pt) 2014-03-27
UA76483C2 (en) 2006-08-15
CN1789264A (zh) 2006-06-21
TWI269796B (en) 2007-01-01
WO2003016305A1 (en) 2003-02-27
PL216524B1 (pl) 2014-04-30
AP1660A (en) 2006-09-09
TNSN04028A1 (fr) 2006-06-01
US20030069298A1 (en) 2003-04-10
DK3168218T3 (en) 2019-01-14
PL368317A1 (en) 2005-03-21
ES2705063T3 (es) 2019-03-21
BG108553A (bg) 2005-04-30
EP3168218B1 (en) 2018-11-14
KR100639281B1 (ko) 2006-10-31
ES2623094T3 (es) 2017-07-10
NZ531232A (en) 2004-11-26
CZ2004196A3 (cs) 2005-01-12
AP2004002976A0 (en) 2004-03-31
EP1419151B1 (en) 2014-02-26
IL160097A0 (en) 2004-06-20
KR20040030074A (ko) 2004-04-08
US7435832B2 (en) 2008-10-14
CO5550431A2 (es) 2005-08-31

Similar Documents

Publication Publication Date Title
CU20040029A7 (es) Cristales anhidros que incluyen una sal del ácido málico de una 2-indolinona sustituida con 3-pirrol, métodos de preparación y composiciones que las contienen
RU2397168C2 (ru) Производные тиофена в качестве ингибиторов снк 1
RU2008119842A (ru) Производные триазола в качестве ингибиторов 11-бета-гидроксистероиддегидрогеназы-1
RU2009102252A (ru) Хиноксалинилмакроциклические ингибиторы серинпротеазы вируса гепатита с
CO5390079A1 (es) Compuestos heterociclicos novedosos que tienen actividades hipolipidemicas, hipocolesterolicas, proceso para su preparacion y composiciones farmaceuticas que los contienen y su uso en medicina
PE20021006A1 (es) Derivados de 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la proteinquinasa
RU2008139905A (ru) Фармацевтическая композиция для наружного применения
EA201171333A1 (ru) Кристаллические сольваты и комплексы производных (1s)-1,5-ангидро-1-с-(3-((фенил)метил)фенил)-d-глюцитола с аминокислотами в качестве ингибиторов sglt2 для лечения диабета
SE0202463D0 (sv) Novel compounds
UY29182A1 (es) "derivados de bencenosulfonamidas sustituídas, composiciones que las contienen, procedimientos de preparación y aplicaciones"
EA201100482A1 (ru) Кристаллические формы 2-тиазолил-4-хинолинилоксипроизводного, активного ингибитора hcv
EA200500088A1 (ru) Трициклические модуляторы ядерного рецептора стероидного гормона
EA200802173A1 (ru) Производные терфенила для лечения болезни альцгеймера
PE20070218A1 (es) COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA
RU2009121756A (ru) Новое кристаллическое соединение, полезное в качестве активатора глюкокиназы (glk)
AR049274A1 (es) Acido2-{[2-(2-metilaminopirimidin-4-il)-1h-indol-5-carbonil]amino}-3-(fenilpiridin-2-ilamino)propionico sustancialmente puro como inhibidor selectivo de la quinasa ikk-2
EA200300104A1 (ru) НОВАЯ γ КРИСТАЛЛИЧЕСКАЯ ФОРМА ТРЕТ-БУТИЛАМИНОВОЙ СОЛИ ПЕРИНДОПРИЛА, СПОСОБ ЕЕ ПОЛУЧЕНИЯ И СОДЕРЖАЩИЕ ЕЕ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ
SE0402762D0 (sv) Indazole sulphonamide derivatives
RU2008106754A (ru) Предотвращающий преждевременную овуляцию агент
FI970317A (fi) Antiproliferatiivisina aineina ja Garft-inhibiittoreina käyttökelpoisia yhdisteitä
EA200300103A1 (ru) НОВАЯ β КРИСТАЛЛИЧЕСКАЯ ФОРМА ТРЕТ-БУТИЛАМИНОВОЙ СОЛИ ПЕРИНДОПРИЛА, СПОСОБ ЕЕ ПОЛУЧЕНИЯ И СОДЕРЖАЩИЕ ЕЕ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ
RU2009102270A (ru) Производные тиазолилмочевины в качестве ингибиторов фосфатидилинозитол-3-киназы
DE602006014022D1 (de) 5-substituierte indol-2-carbonsäureamidderivate
AR041678A1 (es) Formas cristalinas de clorhidrato de donepezil
NO20074622L (no) Metabolitter for NK-1 antagonister for brekninger

Legal Events

Date Code Title Description
FG Grant of patent